VAB-6 and cisplatin-cyclophosphamide combinations in the treatment of metastatic seminoma patients: the U.S.S.R. experience

• Published in: Annals of oncology Vol. 2; no. 9; pp. 667 - 672
• Main Authors: Tjulandin, S A, Khlebnov, A V, Nasirova, R J, Mikhina, Z P, Molchanov, G V, Sholokhov, V N, Sokolov, V A, Vetrova, N A, Garin, A M
• Format: Journal Article
• Language: English
• Published: England 01.10.1991
• Subjects: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Bleomycin - administration & dosage; Chi-Square Distribution; Cisplatin - administration & dosage; Cyclophosphamide - administration & dosage; Dactinomycin - administration & dosage; Dysgerminoma - drug therapy; Dysgerminoma - mortality; Dysgerminoma - pathology; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Remission Induction; Survival Rate; Testicular Neoplasms - drug therapy; Testicular Neoplasms - mortality; Testicular Neoplasms - pathology; USSR; Vinblastine - administration & dosage; USSR
• ISSN: 0923-7534
• DOI: 10.1093/oxfordjournals.annonc.a058046

In a non-randomized study the treatment results of 59 patients with disseminated seminoma were evaluated: 21 patients were treated with a VAB-6 combination and 38 with a CP (cyclophosphamide and cisplatin) combination. After VAB-6 CR was observed in 8 patients and 6 achieved CR with additional treatment: 1 with chemotherapy (PVB) and 5 with radiotherapy (RT). The final CR rate was 67%. At a median follow-up of 38 (11-70) months 15 (71%) are alive, and 11 of them (52%) are NED; 6 have died. Of the 38 patients treated with CP alone only 18 achieved CR and 9 had a CR after additional RT and 1 chemotherapy (VAB-6), the overall CR rate was 72%. The median follow-up is 24 (4-55) months, 28 (74%) are alive, 24 (66%) are currently NED, and 9 have died. Both regimens were well tolerated, the main toxicity being leukopenia: 48% (WHO grade 111-1V-5%) for VAB-6, and 59% (13%) for CP. Hearing loss was registered in 8 patients receiving CP and in 2 receiving VAB-6. There were no fatal toxicities. Thus, VAB-6 and CP regimens seem to have compatible and high activity in disseminated seminoma.